These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12472987)

  • 1. Alternative venlafaxine kinetics in overdose.
    Langford NJ; Martin U; Ruprah M; Ferner RE
    J Clin Pharm Ther; 2002 Dec; 27(6):465-7. PubMed ID: 12472987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.
    Lindh JD; Annas A; Meurling L; Dahl ML; AL-Shurbaji A
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):401-6. PubMed ID: 12898080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population.
    Fukuda T; Nishida Y; Zhou Q; Yamamoto I; Kondo S; Azuma J
    Eur J Clin Pharmacol; 2000 May; 56(2):175-80. PubMed ID: 10877013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.
    Jornil J; Nielsen TS; Rosendal I; Ahlner J; Zackrisson AL; Boel LW; Brock B
    Forensic Sci Int; 2013 Mar; 226(1-3):e26-31. PubMed ID: 23332809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
    Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
    J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans.
    Lessard E; Yessine MA; Hamelin BA; Gauvin C; Labbé L; O'Hara G; LeBlanc J; Turgeon J
    J Clin Psychopharmacol; 2001 Apr; 21(2):175-84. PubMed ID: 11270914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular and neurological toxicity of venlafaxine.
    Blythe D; Hackett LP
    Hum Exp Toxicol; 1999 May; 18(5):309-13. PubMed ID: 10372752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
    Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
    J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fatal case of venlafaxine overdose.
    Bosse GM; Spiller HA; Collins AM
    J Med Toxicol; 2008 Mar; 4(1):18-20. PubMed ID: 18338306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
    Lessard E; Yessine MA; Hamelin BA; O'Hara G; LeBlanc J; Turgeon J
    Pharmacogenetics; 1999 Aug; 9(4):435-43. PubMed ID: 10780263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe rhabdomyolysis following venlafaxine overdose.
    Pascale P; Oddo M; Pacher P; Augsburger M; Liaudet L
    Ther Drug Monit; 2005 Oct; 27(5):562-4. PubMed ID: 16175126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.
    Fukuda T; Yamamoto I; Nishida Y; Zhou Q; Ohno M; Takada K; Azuma J
    Br J Clin Pharmacol; 1999 Apr; 47(4):450-3. PubMed ID: 10233212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal venlafaxine overdose with acinar zone 3 liver cell necrosis.
    Shaw MW; Sheard JD
    Am J Forensic Med Pathol; 2005 Dec; 26(4):367-8. PubMed ID: 16304474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of analytical methods in the determination of two venlafaxine fatalities.
    Long C; Crifasi J; Maginn D; Graham M; Teas S
    J Anal Toxicol; 1997; 21(2):166-9. PubMed ID: 9083836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.
    Preskorn SH
    J Psychiatr Pract; 2010 Jan; 16(1):46-9. PubMed ID: 20098230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients.
    Haslemo T; Eliasson E; Jukić MM; Ingelman-Sundberg M; Molden E
    Br J Clin Pharmacol; 2019 Jan; 85(1):194-201. PubMed ID: 30312494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin syndrome due to venlafaxine overdose.
    Daniels RJ
    J Accid Emerg Med; 1998 Sep; 15(5):333-4. PubMed ID: 9785164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intralipid reverses coma associated with zopiclone and venlafaxine overdose.
    Hillyard SG; Barrera-Groba C; Tighe R
    Eur J Anaesthesiol; 2010 Jun; 27(6):582-3. PubMed ID: 20090535
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of venlafaxine on imipramine metabolism.
    Albers LJ; Reist C; Vu RL; Fujimoto K; Ozdemir V; Helmeste D; Poland R; Tang SW
    Psychiatry Res; 2000 Nov; 96(3):235-43. PubMed ID: 11084219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases.
    Howell C; Wilson AD; Waring WS
    Br J Clin Pharmacol; 2007 Aug; 64(2):192-7. PubMed ID: 17298480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.